PDCD1 and cutaneous melanoma: Using Opal multiplex immunohistochemistry in 66 stage II primary cutaneous melanomas, Attrill et al. showed that a higher proportion of a specific subset of CD8+ T cells, CD39+ CD103+ PD-1− CD8+ T cells are seen in patients with a RFS greater or equal to 5 years [10].